HCT frailty scale for younger and older adults undergoing allogeneic hematopoietic cell transplantation.

Autor: Salas MQ; Department of Medicine, Section of Medical Oncology and Hematology, University of Toronto, Toronto, ON, Canada.; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology. Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.; HCT Unit, Hospital Clinic de Barcelona, ICHMO, Barcelona, Spain., Atenafu EG; Department of Biostatistics, Princes Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Pasic I; Department of Medicine, Section of Medical Oncology and Hematology, University of Toronto, Toronto, ON, Canada.; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology. Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Bascom O; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology. Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Wilson L; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology. Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Lam W; Department of Medicine, Section of Medical Oncology and Hematology, University of Toronto, Toronto, ON, Canada.; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology. Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Law AD; Department of Medicine, Section of Medical Oncology and Hematology, University of Toronto, Toronto, ON, Canada.; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology. Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Chen C; Department of Medicine, Section of Medical Oncology and Hematology, University of Toronto, Toronto, ON, Canada.; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology. Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Novitzky-Basso I; Department of Medicine, Section of Medical Oncology and Hematology, University of Toronto, Toronto, ON, Canada.; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology. Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Kim DDH; Department of Medicine, Section of Medical Oncology and Hematology, University of Toronto, Toronto, ON, Canada.; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology. Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Gerbitz A; Department of Medicine, Section of Medical Oncology and Hematology, University of Toronto, Toronto, ON, Canada.; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology. Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Viswabandya A; Department of Medicine, Section of Medical Oncology and Hematology, University of Toronto, Toronto, ON, Canada.; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology. Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Michelis FV; Department of Medicine, Section of Medical Oncology and Hematology, University of Toronto, Toronto, ON, Canada.; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology. Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Lipton JH; Department of Medicine, Section of Medical Oncology and Hematology, University of Toronto, Toronto, ON, Canada.; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology. Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Mattsson J; Department of Medicine, Section of Medical Oncology and Hematology, University of Toronto, Toronto, ON, Canada.; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology. Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Alibhai SMH; Department of Medicine, University Health Network, Toronto, ON, Canada., Kumar R; Department of Medicine, Section of Medical Oncology and Hematology, University of Toronto, Toronto, ON, Canada. rajat.kumar@uhn.ca.; Hans Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology. Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. rajat.kumar@uhn.ca.
Jazyk: angličtina
Zdroj: Bone marrow transplantation [Bone Marrow Transplant] 2023 Nov; Vol. 58 (11), pp. 1237-1246. Date of Electronic Publication: 2023 Aug 24.
DOI: 10.1038/s41409-023-02088-z
Abstrakt: The HCT Frailty Scale is an easy prognostic tool composed of (a) Clinical Frailty Scale; (b) Instrumental Activities of Daily Living; (c) Timed-up-and-Go test; (d) Grip Strength; (e) Self-Health Rated Questionnaire; (f) Falls tests; (g) Albumin and C-reactive protein levels. This scale was designed to classify allogeneic hematopoietic cell transplant (alloHCT) candidates into fit, pre-frail and frail groups, irrespective of age. This study evaluates the ability of this frailty classification to predict overall survival (OS) and non-relapse mortality (NRM) in adult patients of all ages, in a prospective sample of 298 patients transplanted between 2018 and 2020. At first consultation, 103 (34.6%) patients were fit, 148 (49.7%) pre-frail, and 47 (15.8%) were frail. The 2-year OS and NRM of the three groups were 82.9%, 67.4%, and 48.3% (P < 0.001), and 5.4%, 19.2%, and 37.7% (P < 0.001). For patients younger than 60 years (n = 174), the 2-year OS and NRM of fit, pre-frail, and frail groups were 88.4%, 69.3% and 53.1% (P = 0.002), and 5.8%, 22.8%, and 34.8% (P = 0.005), respectively; and in patients older than 60 (n = 124), OS and NRM were 75.5%, 63.8% and 41.4% (P = 0.006), and 4.9%, 16.4%, and 42.1% (P = 0.001). In conclusion, frailty predicted worse transplant outcomes in both younger and older adults.
(© 2023. The Author(s), under exclusive licence to Springer Nature Limited.)
Databáze: MEDLINE
Externí odkaz: